共济失调-毛细血管扩张突变杂合子及其患共济失调-毛细血管扩张的子女心血管风险的一致性

IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Expert Opinion on Orphan Drugs Pub Date : 2020-06-02 DOI:10.1080/21678707.2020.1780117
Talita Lemos Neves Barreto, Elaine Cristina de Almeida Kotchetkoff, C. Lago, R. Sarni
{"title":"共济失调-毛细血管扩张突变杂合子及其患共济失调-毛细血管扩张的子女心血管风险的一致性","authors":"Talita Lemos Neves Barreto, Elaine Cristina de Almeida Kotchetkoff, C. Lago, R. Sarni","doi":"10.1080/21678707.2020.1780117","DOIUrl":null,"url":null,"abstract":"ABSTRACT Objective Ataxia-telangiectasia (A-T) is an autosomal recessive neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated (ATM) gene. The parents do not manifest the disease but are heterozygous carriers of a pathogenic ATM mutation that may be associated with coronary atherosclerosis and increased cholesterol levels. The objective of this study was to verify whether there is an agreement between the biomarkers of the lipid profile and the carotid intima-media thickness (IMT) of mothers and their children with A-T. Methods This cross-sectional study included A-T patients (n = 11), their mothers (n = 9), and controls (n = 20). Anthropometric data, lipid profile markers, and apolipoproteins (Apo) A-1 and B were collected and carotid IMT was performed. Results Dyslipidemia was found in 7/11 of patients with A-T and 6/9 of mothers with a strong level of agreement (po = 1.00; Kappa = 1.00;p = 0.001). Regarding the variables of the lipid profile, only NHDL-c (ICC = 0.64;p = 0.01) and the ApoB/ApoA-1 ratios (po = 0.72;Kappa = 0.14;p = 0.62) and TG/HDL-c (ICC = 0.54;p = 0.04) showed agreement between mothers and children. A significant difference (p < 0.001) of the carotid IMT was found in A-T patients when compared to their mothers. Conclusion The agreement for lipid metabolism biomarkers associated with cardiovascular risk between children with A-T and their mothers emphasizes the importance of continuous monitoring of both.","PeriodicalId":12118,"journal":{"name":"Expert Opinion on Orphan Drugs","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2020-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21678707.2020.1780117","citationCount":"1","resultStr":"{\"title\":\"Agreement of cardiovascular risk in ataxia-telangiectasia mutated heterozygotes and their children with Ataxia-telangiectasia\",\"authors\":\"Talita Lemos Neves Barreto, Elaine Cristina de Almeida Kotchetkoff, C. Lago, R. Sarni\",\"doi\":\"10.1080/21678707.2020.1780117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Objective Ataxia-telangiectasia (A-T) is an autosomal recessive neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated (ATM) gene. The parents do not manifest the disease but are heterozygous carriers of a pathogenic ATM mutation that may be associated with coronary atherosclerosis and increased cholesterol levels. The objective of this study was to verify whether there is an agreement between the biomarkers of the lipid profile and the carotid intima-media thickness (IMT) of mothers and their children with A-T. Methods This cross-sectional study included A-T patients (n = 11), their mothers (n = 9), and controls (n = 20). Anthropometric data, lipid profile markers, and apolipoproteins (Apo) A-1 and B were collected and carotid IMT was performed. Results Dyslipidemia was found in 7/11 of patients with A-T and 6/9 of mothers with a strong level of agreement (po = 1.00; Kappa = 1.00;p = 0.001). Regarding the variables of the lipid profile, only NHDL-c (ICC = 0.64;p = 0.01) and the ApoB/ApoA-1 ratios (po = 0.72;Kappa = 0.14;p = 0.62) and TG/HDL-c (ICC = 0.54;p = 0.04) showed agreement between mothers and children. A significant difference (p < 0.001) of the carotid IMT was found in A-T patients when compared to their mothers. Conclusion The agreement for lipid metabolism biomarkers associated with cardiovascular risk between children with A-T and their mothers emphasizes the importance of continuous monitoring of both.\",\"PeriodicalId\":12118,\"journal\":{\"name\":\"Expert Opinion on Orphan Drugs\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2020-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21678707.2020.1780117\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Orphan Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21678707.2020.1780117\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Orphan Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21678707.2020.1780117","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

摘要

【摘要】目的共济失调毛细血管扩张症(ataxia- telangi扩张症,简称A-T)是一种常染色体隐性遗传的神经退行性疾病,由共济失调毛细血管扩张突变基因(ataxia- telangi扩张突变基因)突变引起。父母没有表现出这种疾病,但是一种致病性ATM突变的杂合携带者,这种突变可能与冠状动脉粥样硬化和胆固醇水平升高有关。本研究的目的是验证患有A-T的母亲及其子女的脂质谱生物标志物与颈动脉内膜-中膜厚度(IMT)之间是否存在一致。方法本横断面研究包括A-T患者(n = 11)、其母亲(n = 9)和对照组(n = 20)。收集人体测量数据、血脂标记物和载脂蛋白(Apo) A-1和B,并进行颈动脉IMT。结果7/11的a - t患者和6/9的a - t母亲存在血脂异常,一致性强(po = 1.00;Kappa = 1.00;p = 0.001)。在血脂变量方面,只有NHDL-c (ICC = 0.64, p = 0.01)、ApoB/ApoA-1比值(po = 0.72, Kappa = 0.14, p = 0.62)和TG/HDL-c (ICC = 0.54, p = 0.04)在母亲与儿童之间具有一致性。与母亲相比,A- t患者颈动脉IMT有显著差异(p < 0.001)。结论A-T患儿与其母亲在与心血管风险相关的脂质代谢生物标志物方面的一致强调了对两者进行持续监测的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Agreement of cardiovascular risk in ataxia-telangiectasia mutated heterozygotes and their children with Ataxia-telangiectasia
ABSTRACT Objective Ataxia-telangiectasia (A-T) is an autosomal recessive neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated (ATM) gene. The parents do not manifest the disease but are heterozygous carriers of a pathogenic ATM mutation that may be associated with coronary atherosclerosis and increased cholesterol levels. The objective of this study was to verify whether there is an agreement between the biomarkers of the lipid profile and the carotid intima-media thickness (IMT) of mothers and their children with A-T. Methods This cross-sectional study included A-T patients (n = 11), their mothers (n = 9), and controls (n = 20). Anthropometric data, lipid profile markers, and apolipoproteins (Apo) A-1 and B were collected and carotid IMT was performed. Results Dyslipidemia was found in 7/11 of patients with A-T and 6/9 of mothers with a strong level of agreement (po = 1.00; Kappa = 1.00;p = 0.001). Regarding the variables of the lipid profile, only NHDL-c (ICC = 0.64;p = 0.01) and the ApoB/ApoA-1 ratios (po = 0.72;Kappa = 0.14;p = 0.62) and TG/HDL-c (ICC = 0.54;p = 0.04) showed agreement between mothers and children. A significant difference (p < 0.001) of the carotid IMT was found in A-T patients when compared to their mothers. Conclusion The agreement for lipid metabolism biomarkers associated with cardiovascular risk between children with A-T and their mothers emphasizes the importance of continuous monitoring of both.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Expert Opinion on Orphan Drugs
Expert Opinion on Orphan Drugs PHARMACOLOGY & PHARMACY-
CiteScore
2.30
自引率
0.00%
发文量
8
期刊介绍: Expert Opinion on Orphan Drugs is an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.
期刊最新文献
Emerging therapies against Naegleria fowleri Management of pulmonary hypertension in infants Current and emerging therapies for the treatment of leishmaniasis The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022 Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1